Amyloid Cardiomyopathy.

Area of Science:

• Cardiology
• Genetics
• Internal Medicine

Background:

• Amyloid cardiomyopathy is an under-recognized cause of heart failure and arrhythmias, particularly in older adults.
• It involves extracellular deposition of misfolded amyloid fibrils, primarily from light chains (AL) or transthyretin protein (ATTR).
• ATTR amyloidosis can stem from wild-type transthyretin (ATTRwt) or TTR gene variants (ATTRv), affecting the heart or multiple systems.

Purpose of the Study:

• To highlight the growing clinical importance of amyloid cardiomyopathy.
• To emphasize the need for heightened awareness, contemporary diagnostics, and emerging disease-modifying therapies.
• To discuss the implications of genetic testing for ATTR amyloidosis, including treatment access and family screening.

Main Methods:

• Review of current understanding of amyloid cardiomyopathy pathophysiology and clinical presentation.
• Discussion of advancements in diagnostic methods for amyloid detection.
• Overview of newly developed disease-modifying interventions for ATTR amyloidosis.

Main Results:

• Amyloid cardiomyopathy prevalence is higher than previously thought.
• Disease-modifying therapies are now available, transforming prognosis.
• Genetic testing is crucial for identifying ATTRv and enabling targeted treatments.

Conclusions:

• Early identification and diagnosis of amyloid cardiomyopathy are critical.
• Genetic testing for ATTR amyloidosis allows access to specific therapies and family screening.
• Emerging therapies offer the potential to prevent disease progression and shift amyloid cardiomyopathy from fatal to treatable.